$0.83—Stale · unknown old
NASDAQ • Last print unknown ago
$0.83—Stale · unknown old
INVO Bioscience, Inc. specializes in developing and commercializing innovative medical devices for assisted reproductive technology, particularly its patented INVOcell device, which allows for in vivo fertilization. The company's unique approach targets markets with high demand for affordable fertility treatments, particularly in emerging economies where traditional IVF is cost-prohibitive.
INVO generates revenue primarily through the sale of its INVOcell devices, which are designed to be a cost-effective alternative to traditional IVF methods. The company also earns income from licensing its technology to clinics and providing training and support services, leveraging its proprietary technology to maintain pricing power in a competitive market.
Regulatory approvals for new markets, particularly in Europe and Asia
Partnerships with fertility clinics to expand distribution
Changes in healthcare policies affecting fertility treatment accessibility
Market adoption rates of INVOcell in emerging economies
Regulatory changes that could impact the approval process for medical devices
Technological disruption from competitors developing more advanced fertility solutions
Emergence of new fertility technologies that could overshadow INVOcell
Pricing pressures from established IVF providers
Negative operating cash flow of $-7.0B raises concerns about liquidity
High net margin loss of -367.3% indicates potential sustainability issues
moderate - The demand for fertility treatments is somewhat correlated with consumer spending and economic conditions, as families are more likely to invest in such treatments during stable economic periods.
Rising interest rates may increase the cost of financing for expansion and R&D, potentially impacting growth plans and valuation multiples.
minimal - The company has a manageable debt-to-equity ratio of 0.27, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in the healthcare sector may find INVO appealing due to its innovative product.
high - The stock has exhibited significant volatility, with a 1-year return of -51.6%, indicating a high beta relative to the market.